Retatrutide Explained: The Triple-Agonist Research Peptide
Retatrutide engages three incretin receptors - GIP, GLP-1, and glucagon - and Phase-2 research reported the largest mean weight reductions yet seen in its class. A clear breakdown of why that matters.
Retatrutide (development code LY3437943) is the most-discussed metabolic research peptide of the decade. It is a triple-receptor agonist - and understanding why that matters starts with the receptors it engages.
What 'triple agonist' means
The incretin system uses several gut hormones to regulate metabolism. Earlier-generation compounds targeted one or two receptors: semaglutide is a single GLP-1 agonist; tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds a third target - the glucagon receptor - making it a triple agonist acting on GIP, GLP-1, and glucagon simultaneously.
What the published research reported
Phase-2 research published in the New England Journal of Medicine (Jastreboff et al., 2023) reported up to roughly 24% mean body-weight reduction at 48 weeks at the highest dose studied - figures that exceeded those reported for semaglutide and tirzepatide monotherapy in their respective trials. Head-to-head trials are ongoing, so direct comparisons should be read with appropriate caution.
The body-composition angle
A frequent concern with rapid weight loss is the proportion that comes from lean mass rather than fat. The glucagon-receptor component of Retatrutide is hypothesized to raise resting energy expenditure, and the published body-composition data points toward a fat-mass-selective profile. This remains an active research question rather than a settled conclusion.
Quality and verification
Caesar Biomedical Retatrutide is synthesized to pharmaceutical-grade specification in South Korea and independently verified in Dubai or the UK, with per-lot HPLC and ESI-MS documented on the Certificate of Analysis.
Explore the compound
Retatrutide
Triple-agonist next-generation incretin · GIP / GLP-1 / Glucagon
Frequently asked questions
- How is Retatrutide different from Ozempic or Mounjaro?
- Ozempic (semaglutide) is a single GLP-1 agonist and Mounjaro (tirzepatide) is a dual GIP/GLP-1 agonist. Retatrutide adds the glucagon receptor as a third target. Published Phase-2 research reported larger mean weight reductions, though it remains investigational.
- Is Retatrutide FDA-approved?
- No. As of 2026 Retatrutide is an investigational compound in clinical trials and is sold strictly for laboratory research use only.
For laboratory research use only. This article references published preclinical and clinical literature and is not medical advice, a therapeutic claim, or a recommendation for human use.